BAY 81‐8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

OBJECTIVES: BAY 81‐8973 (Kovaltry(®)), a full‐length, unmodified, recombinant human factor VIII, provided excellent bleeding control for patients with haemophilia A in the pivotal 1‐year LEOPOLD I trial. The LEOPOLD I extension evaluated long‐term efficacy and safety of BAY 81‐8973 prophylaxis. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahlangu, Johnny, Lopez Fernandez, Maria Fernanda, Santagostino, Elena, Lalezari, Shadan, Tseneklidou‐Stoeter, Despina, Beckmann, Horst, Church, Nikki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383510/
https://www.ncbi.nlm.nih.gov/pubmed/32112434
http://dx.doi.org/10.1111/ejh.13402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383510/
https://www.ncbi.nlm.nih.gov/pubmed/32112434
http://dx.doi.org/10.1111/ejh.13402

Ejemplares similares